Should You Buy Kymera Therapeutics Inc (KYMR) Today? Analysis, Price Targets, and 2026 Outlook.
Conclusion
Hold
Latest Price
71.160
1 Day change
-1.37%
52 Week Range
103.000
Analysis Updated At
2026/01/26
Kymera Therapeutics Inc (KYMR) is not a strong buy for a beginner investor with a long-term strategy at this time. Despite positive analyst sentiment in late 2025 regarding its Phase 1b results for KT-621, recent downgrades and concerns about valuation and lack of immediate catalysts make it a less compelling choice. The technical indicators and options data suggest a neutral to slightly bearish short-term outlook, and the company's financials show declining revenue and persistent losses, which may not align with the user's investment goals.
Technical Analysis
The MACD is negative and contracting, RSI is neutral at 39.19, and moving averages are converging, indicating no clear trend. The stock is trading near its support level of 67.548, with resistance at 72.025. Overall, the technical indicators suggest a neutral to slightly bearish trend.
Options Data
Neutral
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio
The low put-call volume ratio indicates a lack of bearish sentiment in the options market, but the high implied volatility (136.17) suggests significant uncertainty.
Technical Summary
Sell
10
Buy
3
Positive Catalysts
Analysts view the drug as a potential leader in immunology and inflammation indications.
Neutral/Negative Catalysts
Recent downgrade by Wolfe Research citing valuation concerns, lack of immediate catalysts, and skepticism about M&A potential. No significant news or events in the past week to drive momentum.
Financial Performance
In Q3 2025, revenue dropped by 26.12% YoY to $2.76M, while net income improved but remained negative at -$82.18M. EPS increased to -0.94, up 14.63% YoY. The company maintains a 100% gross margin, but the declining revenue and persistent losses are concerning.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Analyst sentiment was positive in late 2025, with multiple upgrades and price target increases (up to $134) based on promising Phase 1b data. However, Wolfe Research recently downgraded the stock in early 2026, citing valuation concerns and lack of catalysts, which dampens the overall outlook.
Wall Street analysts forecast KYMR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KYMR is 116.3 USD with a low forecast of 90 USD and a high forecast of 138 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
22 Analyst Rating
Wall Street analysts forecast KYMR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KYMR is 116.3 USD with a low forecast of 90 USD and a high forecast of 138 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
21 Buy
1 Hold
0 Sell
Strong Buy
Current: 72.150
Low
90
Averages
116.3
High
138
Current: 72.150
Low
90
Averages
116.3
High
138
Barclays
Eliana Merle
Overweight
initiated
$119 -> $133
AI Analysis
2026-01-27
New
Reason
Barclays
Eliana Merle
Price Target
$119 -> $133
AI Analysis
2026-01-27
New
initiated
Overweight
Reason
Barclays analyst Eliana Merle assumed coverage of Kymera Therapeutics with an Overweight rating and price target of $133, up from $119. Barclays initiated coverage of 12 biotech stocks and assumed coverage of 11 with a positive view of the industry. The analyst likes the setup for the group in 2026. Many biotech stocks remain undervalued, the analyst tells investors in a research note. The firm expects continued mergers and acquisitions, "strong" underlying fundamentals, and less of a focus on drug pricing to act as "significant tailwinds."
Wolfe Research
Outperform -> Peer Perform
downgrade
2026-01-06
Reason
Wolfe Research
Price Target
2026-01-06
downgrade
Outperform -> Peer Perform
Reason
Wolfe Research downgraded Kymera Therapeutics to Peer Perform from Outperform.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for KYMR
